美国专利非显而易见性Graham-TSM判定标准及其对我国的启示——基于“Pfizer vs.Apotex案”的实证分析  

The Graham-TSM Standard for the examination of non-obviousness in U.S. patent law and its enlightenment to China——based on the empirical analysis of ‘Pfizer vs. Apotex case'

作　　者：丁锦希[1] 傅凌宇 孟立立[1] 王安庐[1] 

机构地区：[1]中国药科大学,南京211198

出　　处：《上海医药》2015年第13期62-67,共6页Shanghai Medical & Pharmaceutical Journal

基　　金：国家社会科学基金项目:TRIPS框架下中国药品试验数据保护制度研究(项目编号:13BFX120)

摘　　要：创造性判断标准是专利法的中争议最大,最难以掌握一项审查标准。现阶段,我国专利创造性司法审查标准中存在较大法律误区,增大了涉及专利创造性案件审判的不确定性。本文以近期美国发生的"Pfizer vs.Apotex案"生物医药专利纠纷案例为实证分析主线,通过剖析美国专利非显而易见性判定原则的历史演进,为完善我国专利创造性的司法审查标准提供可行性建议。Among all the patentability examination standards in the patent law, the creativity criteria is the most debatable and the hardest one to be mastered. Currently, there exists serious misunderstanding of the patent＇s creativity criteria in our country, which increases the uncertainty of the trial of cases concerning patents＇ creativity. In this paper, the recent U.S. biomedicine patent infringement case--＇Pfizer vs. Apotex case＇ is used as a main line of the empirical analysis. Through analyzing the evolution history of patent non-obviousness criteria in the U.S., some feasible suggestions are proposed to improve the judicial creativity criteria of our country.

关 键 词：非显而易见性 创造性 Graham-TSM判定标准 

分 类 号：R-051[医药卫生] D971.2[政治法律—法学] D923.42